Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Free Cash Flow: 2015-2025

Historic Free Cash Flow for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to -$31.3 million.

  • Voyager Therapeutics' Free Cash Flow fell 10.73% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.9 million, marking a year-over-year decrease of 314.69%. This contributed to the annual value of -$18.8 million for FY2024, which is 125.22% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Free Cash Flow is -$31.3 million, which was up 9.05% from -$34.4 million recorded in Q2 2025.
  • Voyager Therapeutics' 5-year Free Cash Flow high stood at $123.1 million for Q1 2023, and its period low was -$38.6 million during Q1 2025.
  • Over the past 3 years, Voyager Therapeutics' median Free Cash Flow value was -$24.5 million (recorded in 2023), while the average stood at -$4.4 million.
  • Per our database at Business Quant, Voyager Therapeutics' Free Cash Flow skyrocketed by 259.83% in 2023 and then crashed by 1,491.54% in 2024.
  • Over the past 5 years, Voyager Therapeutics' Free Cash Flow (Quarterly) stood at $10.8 million in 2021, then slumped by 221.47% to -$13.2 million in 2022, then tumbled by 86.04% to -$24.5 million in 2023, then soared by 40.10% to -$14.7 million in 2024, then decreased by 10.73% to -$31.3 million in 2025.
  • Its Free Cash Flow stands at -$31.3 million for Q3 2025, versus -$34.4 million for Q2 2025 and -$38.6 million for Q1 2025.